Get all your news in one place.

100’s of premium titles.
One app. Zero ads.

Get all your news in one place.

100’s of premium titles. One news app. Zero ads.

The Latest Breaking News on GoodRx

5 things to know about the FDA's flawed approach to accelerated drug approvals

An NPR investigation found stalled confirmatory trials and lax enforcement are plaguing the FDA's accelerated approval of drugs for urgent medical needs.

Baird Maintains Neutral Rating for GoodRx Holdings: Here's What You Need To Know

Baird Maintains Neutral Rating for GoodRx Holdings: Here's What You Need To Know

Baird has decided to maintain its Neutral rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $7.00 to $6.00. Shares of GoodRx Holdings are trading up 6.94% over the last 24 hours, at $6.32 per share. A move to $6.00 would account for a 5.06% decline from the…

Your Phone Apps Might Know You’re Pregnant Before You Do

Your Phone Apps Might Know You’re Pregnant Before You Do

Over 130 years ago, a young lawyer saw an amazing new gadget and had a revolutionary vision: Technology can threaten our privacy.

The New York Times

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Goldman Sachs Maintains Buy Rating for GoodRx Holdings: Here's What You Need To Know

Goldman Sachs has decided to maintain its Buy rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $30.00 to $12.00. Shares of GoodRx Holdings are trading up 1.32% over the last 24 hours, at $8.07 per share.

GoodRx Shares Tumble As FY22 Guidance Hit By Grocery Chain Prescription Dispute

GoodRx Holdings Inc (NASDAQ: GDRX) shares fell after it expects FY22 revenue to take a hit due to recent actions by one grocery store chain that represents a sizable chunk of its grocery prescription business.

Can billionaire celebrity Mark Cuban fix America’s broken health system?

The celebrity investor has teamed up with a soft-spoken radiologist to tackle the USA’s healthcare crisis – and he has drug industry middlemen squarely in his sights, reports Io Dodds

The Independent UK

3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

inkl

Read news from The Economist, FT, and more,
with one subscription

TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal

TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal

TherapeuticsMD Inc (NASDAQ:TXMD) has agreed to divest its VitaCare Prescription Services business to GoodRx Holdings Inc (NASDAQ:GDRX) for $150 million. VitaCare is a consumer-focused digital healthcare platform. TherapeuticsMD will also receive an additional $7 million in cash consideration contingent upon vitaCare's financial performance through 2023. TXMD will also enter into a long-term services agreement to…

Price Transparency Or Price Obfuscation? Is A PBM-Backed Network Using Its Monopoly In One Business To Advantage Itself In The Next? (1 Of 2)

Price Transparency Or Price Obfuscation? Is A PBM-Backed Network Using Its Monopoly In One Business To Advantage Itself In The Next? (1 Of 2)

What happens when two organizations join forces on the promise of delivering pricing transparency for the nation…except instead of price transparency, what’s delivered is price obfuscation? To borrow from Katherine Gehl, the system isn’t broken. It’s fixed.

Price Transparency Or Price Obfuscation? Is A PBM-Backed Network Using Its Monopoly In One Business To Advantage Itself In The Next? (2 Of 2)

Price Transparency Or Price Obfuscation? Is A PBM-Backed Network Using Its Monopoly In One Business To Advantage Itself In The Next? (2 Of 2)

In fact, one could argue that for e-prescribing routing, it was Surescripts’ central position as a network that helped bring together disparate entities (and their disparate interests) and build a fabric of trust that enabled the adoption of the first ubiquitous form of health information exchange.

GoodRx Plunges As Q4 Fall Short Of Expectations, Analysts Cut Price Target

GoodRx Plunges As Q4 Fall Short Of Expectations, Analysts Cut Price Target

Consumer-focused digital healthcare, GoodRx Holdings Inc (NASDAQ: GDRX) shares are plunging after the company's

Why GoodRX Shares Are Plummeting Today

Why GoodRX Shares Are Plummeting Today

GoodRx Holdings Inc (NASDAQ: GDRX) is plunging Tuesday after the company reported worse-than-expected fourth-quarter financial results and issued guidance below estimates.

1 2 3 4 5

People

Gregg Gonsalves

Alex Oshmyansky

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

Planned Parenthood

GoodRx Holdings

GoodRx Holdings Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

150,224 stories

Artificial Intelligence

Places

320,295 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play